Open chances: pharmacoepidemiological analysis of dynamics of statins consumption in ukraine
DOI:
https://doi.org/10.24959/cphj.14.1288Keywords:
pharmacoepidemiology, statins, consumption, ATC/DDD-methodology, incidenceAbstract
The leading cause of mortality in Ukraine are cardiac and vascular diseases. Hypercholesteremia is an important risk factor for development of cardiovascular disease (CVD). A high preventive efficacy of statins for correction of hypercholesteremia and reduction of the risk of CVD has been proven by a great number of meta-analyzes. The purpose of our research is analysis of the consumption dynamics of the statins group drugs (C 10 A) in Ukraine during 2008-2012. To determine the volume of drug consumption the ATC/DDD-methodology and the data of the reference retrieval system “Medicines” of Morion company for 2008-2012 have been used. Based on the analysis of the Ukrainian pharmaceutical market of statins it has been shown that currently all 7 statins INN, which are available in the world, have been registered in the country; they are presented as a whole by 186 drugs, both of foreign and domestic manufacture. Thus, there is a real opportunity to use drugs of the group of statins in clinical practice. It has been determined that by the volume of consumption in DDDs/1000/ day index as of the beginning of 2013 statins are in the following order: atorvastatin (4.89) > simvastatin (1.92) > rozuvastin (0.25) > lovastatin (0.10) > fluvastatin (0.0023) > pravastatin (0.00012). Over the past five years the total volume of consumption of statins in Ukraine increased by more than twice. The comparison of the volume of the total consumption of statins and the incidence rates of CVD among the population has shown that only 0.12 million (0.26% of the Ukrainian population) take daily one DDD of one of statin drugs. Taking into account the fact that the prophylactic administration of statins should be done daily throughout the life the use of these drugs in Ukraine are now to be regarded as very low and does not correspond to the morbidity level of cardiovascular diseases.
References
Державна служба статистики. Природний рух населення України 2012 [Електронний ресурс]. – Режим доступу до сайту: http://www.ukrstat.gov.ua/.
Кармалита Е.Е. // Укр. мед. часопис. – 2007. – №1. – С. 19-23.
Морозов А.М., Яковлева Л.В., Степаненко А.В. та ін. Вивчення споживання лікарських засобів за анатомо-терапевтично-хімічною класифікацією та встановленими добовими дозами (АТС/ DDD-методологія): Метод. рекоменд. – К.: Укрпатентінфо, 2013. – 32 с.
Оганезова Л.Г. // РМЖ. Кардиол. – 2013. – №19. – С. 964.
Сиренко, Ю.Н. // Здоровье Украины. – 2009. – №3/1. – С. 18-19.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Cholesterol Treatment Trialists’ (CTT) Collaborators // Lancet. – 2005. – Vol. 366, №8. – Р. 1267-1278.
Guidelines for ATC classification and DDD assignment. 16-th ed. // WHO Collaborating Centre for Drug Statistics Methodology. – Oslo, 2012. – 284 р.
Gutierrez J., Ramirez G., Rundek T. et al. // Arch. Intern. Med. – 2012. – Vol. 172. – P. 909-919.
Introduction to drug utilization research // WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services // World Health Organization, 2003. – 48 р.
Kotseva K., Wood D., De Bacer G. et al. // Eur. J. Cardiovasc. Prev. Rehabil. – 2009. – Vol. 16, №2. – Р. 121-137.
Mills E.J., Rachlis B., Wu P. et al. // J. Am. Coll. Cardiol. – 2008. – Vol. 52. – P. 1769-1781.
O’Riordan M. Should Statins Be Used in Primary Prevention? JAMA Gets in on the Debate // Medscape.- Apr. 10. – 2012. – [Електронний ресурс]. – Режим доступу до сайту: http://www.medscape.com/ viewarticle/761834.
Rosamond W., Flegal K., Furie K. et al. // Circulation. – 2008. – Vol. 117, №4. – P. 25-146.
Teng Lida, Xin Hua-wen, Blix Hege Salvesen // Рharmacoepidemiol. and Drug Safety. – 2012. – Wiley Online Library. – 10.1002 [Електронний ресурс]. – Режим доступу до сайту: http://www.f.u-tokyo. ac.jp/~utdpm/paper2/2012_Lida Review.pdf.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
